{"id":344525,"date":"2026-11-12T10:32:03","date_gmt":"2026-11-12T05:02:03","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=344525"},"modified":"2026-11-12T10:32:03","modified_gmt":"2026-11-12T05:02:03","slug":"global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/","title":{"rendered":"3 Global IT Services Company, Specialty Pharmaceuticals Company and Multi Speciality Hospital Chain Stocks With a Strong Future Roadmap: Mphasis, Ajanta Pharma and Global Health"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Mphasis, Ajanta Pharma and Global Health: ROE of 14.1% to 23.3% and FY22 to FY26 revenue CAGR of 7.5% to 19.6%. Prices as of 11 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three IT services, pharma and hospital stocks to watch are Mphasis, Ajanta Pharma and Global Health. Their return on equity ranges from 14.1% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 19.6%. Ajanta Pharma has the highest return on equity at 23.3%, while Global Health has the fastest revenue growth at 19.6% a year. Prices are based on the 11 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>IT services, pharma and hospital stocks offer a focused view of a sector where demand keeps widening. Mphasis, Ajanta Pharma and Global Health cover a global IT services company, a specialty pharmaceuticals company and a multi speciality hospital chain.<\/p>\n<p>This list covers three IT services, pharma and hospital stocks with complete current figures: Mphasis, Ajanta Pharma and Global Health. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#What_Are_IT_Services_Pharma_and_Hospital_Stocks\" title=\"What Are IT Services, Pharma and Hospital Stocks?\">What Are IT Services, Pharma and Hospital Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#IT_Services_Pharma_and_Hospital_Stocks_at_a_Glance\" title=\"IT Services, Pharma and Hospital Stocks at a Glance\">IT Services, Pharma and Hospital Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Why_Do_IT_Services_Pharma_and_Hospital_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do IT Services, Pharma and Hospital Stocks Have a Strong Roadmap in India?\">Why Do IT Services, Pharma and Hospital Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Why_Mphasis_Features_Among_These_IT_Services_Pharma_and_Hospital_Stocks\" title=\"Why Mphasis Features Among These IT Services, Pharma and Hospital Stocks\">Why Mphasis Features Among These IT Services, Pharma and Hospital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Why_Ajanta_Pharma_Features_Among_These_IT_Services_Pharma_and_Hospital_Stocks\" title=\"Why Ajanta Pharma Features Among These IT Services, Pharma and Hospital Stocks\">Why Ajanta Pharma Features Among These IT Services, Pharma and Hospital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Why_Global_Health_Features_Among_These_IT_Services_Pharma_and_Hospital_Stocks\" title=\"Why Global Health Features Among These IT Services, Pharma and Hospital Stocks\">Why Global Health Features Among These IT Services, Pharma and Hospital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Mphasis_vs_Ajanta_Pharma_vs_Global_Health_on_Key_Financials\" title=\"Mphasis vs Ajanta Pharma vs Global Health on Key Financials\">Mphasis vs Ajanta Pharma vs Global Health on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Key_Risks_to_Check_Before_Investing_in_IT_Services_Pharma_and_Hospital_Stocks\" title=\"Key Risks to Check Before Investing in IT Services, Pharma and Hospital Stocks\">Key Risks to Check Before Investing in IT Services, Pharma and Hospital Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Final_Thoughts_on_IT_Services_Pharma_and_Hospital_Stocks\" title=\"Final Thoughts on IT Services, Pharma and Hospital Stocks\">Final Thoughts on IT Services, Pharma and Hospital Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#What_are_IT_services_pharma_and_hospital_stocks\" title=\"What are IT services, pharma and hospital stocks?\">What are IT services, pharma and hospital stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Which_IT_services_pharma_and_hospital_stocks_are_covered_in_this_list\" title=\"Which IT services, pharma and hospital stocks are covered in this list?\">Which IT services, pharma and hospital stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Why_do_IT_services_pharma_and_hospital_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do IT services, pharma and hospital stocks have a strong future roadmap in India?\">Why do IT services, pharma and hospital stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#How_has_Mphasis_performed_financially\" title=\"How has Mphasis performed financially?\">How has Mphasis performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#How_has_Ajanta_Pharma_performed_financially\" title=\"How has Ajanta Pharma performed financially?\">How has Ajanta Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#How_has_Global_Health_performed_financially\" title=\"How has Global Health performed financially?\">How has Global Health performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#What_risks_should_investors_check_before_buying_IT_services_pharma_and_hospital_stocks\" title=\"What risks should investors check before buying IT services, pharma and hospital stocks?\">What risks should investors check before buying IT services, pharma and hospital stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/global-it-services-company-specialty-pharmaceuticals-company-and-multi-speciality-hospital-chain-stocks-roadmap-vantage-list\/#Is_this_list_of_IT_services_pharma_and_hospital_stocks_investment_advice\" title=\"Is this list of IT services, pharma and hospital stocks investment advice?\">Is this list of IT services, pharma and hospital stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_IT_Services_Pharma_and_Hospital_Stocks\"><\/span><strong>What Are IT Services, Pharma and Hospital Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IT services, pharma and hospital stocks are listed companies that provide IT, cloud and application services to global clients, develop and sell branded medicines for chronic and acute conditions, and run large multi speciality hospitals. Their earnings depend on client technology budgets, prescription demand and patient volumes.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"IT_Services_Pharma_and_Hospital_Stocks_at_a_Glance\"><\/span><strong>IT Services, Pharma and Hospital Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/mphasis\/mphasis-ltd-share-price-today\">Mphasis<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,390<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">47,695<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">25.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.24<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/ajantpharm\/ajanta-pharma-ltd-share-price-today\">Ajanta Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,319.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">41,241<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">23.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.06<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/medanta\/global-health-ltd-share-price-today\">Global Health<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,429<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33,277<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">60.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">59.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">14.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.30<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, all three trade at a P\/E above their industry P\/E, which reflects the growth the market already expects from them. Readers comparing IT services, pharma and hospital stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in IT services, pharma and hospital stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_IT_Services_Pharma_and_Hospital_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do IT Services, Pharma and Hospital Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IT services, pharma and hospital stocks have a strong roadmap in India because wider enterprise adoption of digital services, steady demand for branded medicines and rising need for quality hospital care keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>IT services.<\/strong> Large clients consolidate vendors for digital work.<\/li>\n<li><strong>Specialty pharma.<\/strong> Doctors prescribe trusted branded medicines.<\/li>\n<li><strong>Hospitals.<\/strong> Families seek quality specialist care.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Mphasis_Features_Among_These_IT_Services_Pharma_and_Hospital_Stocks\"><\/span><strong>Why Mphasis Features Among These IT Services, Pharma and Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the IT services, pharma and hospital stocks on this list, Mphasis is a Bengaluru-based IT services company that provides applications, cloud, data and consulting services to clients in banking, insurance and technology, especially in the United States.<\/p>\n<p>Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%.<\/p>\n<p>In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore. The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P\/E of 25.0, above the industry P\/E of 17.5.<\/p>\n<p><strong>Roadmap:<\/strong> The company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.<\/p>\n<p><strong>What to watch:<\/strong> Monitor deal wins and client spending trends in banking and financial services.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Ajanta_Pharma_Features_Among_These_IT_Services_Pharma_and_Hospital_Stocks\"><\/span><strong>Why Ajanta Pharma Features Among These IT Services, Pharma and Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the software, branded medicine and care network shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.<\/p>\n<p>In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%.<\/p>\n<p>Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<p><strong>What to watch:<\/strong> Monitor the pace of new launches in branded markets and the momentum in the United States generics business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Global_Health_Features_Among_These_IT_Services_Pharma_and_Hospital_Stocks\"><\/span><strong>Why Global Health Features Among These IT Services, Pharma and Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Global Health, which operates the Medanta brand, runs tertiary-care hospitals led by its flagship campus in Gurugram, along with facilities in Lucknow, Patna, Ranchi, Indore and Noida.<\/p>\n<p>The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P\/E of 60.3, above the industry P\/E of 59.6.<\/p>\n<p>Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore.<\/p>\n<p><strong>Roadmap:<\/strong> Management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.<\/p>\n<p><strong>What to watch:<\/strong> Watch the ramp-up speed of newer hospitals and the pace of doctor additions at each site.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Mphasis_vs_Ajanta_Pharma_vs_Global_Health_on_Key_Financials\"><\/span><strong>Mphasis vs Ajanta Pharma vs Global Health on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three IT services, pharma and hospital stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mphasis<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12,122<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16,206<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,863<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,457<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,625<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.9%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,056<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Global Health<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,206<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,509<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.6%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">554<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Ajanta Pharma posts the highest return on equity in this group at 23.3%. Mphasis has the largest FY26 revenue at Rs 16,206 crore, and Global Health shows the fastest revenue growth with a 19.6% compound annual rate. A useful habit with IT services, pharma and hospital stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several digital services firm, branded drug maker and hospital chain stocks instead of one name, which keeps a single result from deciding the outcome.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Mphasis<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,813<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,467<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Ajanta Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,329<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,697<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">27.7%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Global Health<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,051<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,326<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">26.1%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_IT_Services_Pharma_and_Hospital_Stocks\"><\/span><strong>Key Risks to Check Before Investing in IT Services, Pharma and Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these IT services, pharma and hospital stocks, the main points are: Long-term software, branded medicine and care network shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<li><strong>Pricing pressure.<\/strong> Generic prices can change by market.<\/li>\n<li><strong>Capacity ramp up.<\/strong> New hospitals take time to fill beds and reach full returns.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter IT services, pharma and hospital stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_IT_Services_Pharma_and_Hospital_Stocks\"><\/span><strong>Final Thoughts on IT Services, Pharma and Hospital Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>IT services, pharma and hospital stocks reward patient research into demand, execution and financial strength. Mphasis, Ajanta Pharma and Global Health each have a clear plan to grow. Based on the 11 November 2026 close, Mphasis trades at Rs 2,390, Ajanta Pharma at Rs 3,319.6 and Global Health at Rs 1,429. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these IT services, pharma and hospital stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track IT services, pharma and hospital stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_IT_services_pharma_and_hospital_stocks\"><\/span><strong>What are IT services, pharma and hospital stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> IT services, pharma and hospital stocks are listed companies that provide IT, cloud and application services to global clients, develop and sell branded medicines for chronic and acute conditions, and run large multi speciality hospitals. Their earnings depend on client technology budgets, prescription demand and patient volumes. This list looks at three of them, Mphasis, Ajanta Pharma and Global Health, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_IT_services_pharma_and_hospital_stocks_are_covered_in_this_list\"><\/span><strong>Which IT services, pharma and hospital stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Mphasis, Ajanta Pharma and Global Health. Based on the 11 November 2026 close, Mphasis traded at Rs 2,390, Ajanta Pharma at Rs 3,319.6 and Global Health at Rs 1,429. Their return on equity ranges from 14.1% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 19.6%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_IT_services_pharma_and_hospital_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do IT services, pharma and hospital stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> IT services, pharma and hospital stocks have a strong roadmap in India because wider enterprise adoption of digital services, steady demand for branded medicines and rising need for quality hospital care keep widening the market for these companies. The main drivers are as follows. IT services. Large clients consolidate vendors for digital work. Specialty pharma. Doctors prescribe trusted branded medicines. Hospitals. Families seek quality specialist care. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Mphasis_performed_financially\"><\/span><strong>How has Mphasis performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore. The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P\/E of 25.0, above the industry P\/E of 17.5. Looking ahead, the company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Ajanta_Pharma_performed_financially\"><\/span><strong>How has Ajanta Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Global_Health_performed_financially\"><\/span><strong>How has Global Health performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P\/E of 60.3, above the industry P\/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_IT_services_pharma_and_hospital_stocks\"><\/span><strong>What risks should investors check before buying IT services, pharma and hospital stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying IT services, pharma and hospital stocks. Client spending. Technology budgets can vary with global conditions. Pricing pressure. Generic prices can change by market. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_IT_services_pharma_and_hospital_stocks_investment_advice\"><\/span><strong>Is this list of IT services, pharma and hospital stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are IT services, pharma and hospital stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"IT services, pharma and hospital stocks are listed companies that provide IT, cloud and application services to global clients, develop and sell branded medicines for chronic and acute conditions, and run large multi speciality hospitals. Their earnings depend on client technology budgets, prescription demand and patient volumes. This list looks at three of them, Mphasis, Ajanta Pharma and Global Health, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which IT services, pharma and hospital stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Mphasis, Ajanta Pharma and Global Health. Based on the 11 November 2026 close, Mphasis traded at Rs 2,390, Ajanta Pharma at Rs 3,319.6 and Global Health at Rs 1,429. Their return on equity ranges from 14.1% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 19.6%.\"}},{\"@type\":\"Question\",\"name\":\"Why do IT services, pharma and hospital stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"IT services, pharma and hospital stocks have a strong roadmap in India because wider enterprise adoption of digital services, steady demand for branded medicines and rising need for quality hospital care keep widening the market for these companies. The main drivers are as follows. IT services. Large clients consolidate vendors for digital work. Specialty pharma. Doctors prescribe trusted branded medicines. Hospitals. Families seek quality specialist care. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Mphasis performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 12,122 crore in FY22 to Rs 16,206 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 1,431 crore in FY22 to Rs 1,863 crore in FY26, which works out to a compound annual growth rate of 6.8%. In the June 2026 quarter, revenue grew 17.1% year on year to Rs 4,467 crore, while net profit rose 10.8% to Rs 490 crore. The company has a return on equity of 17.3%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 47,695 crore. The stock trades at a P\/E of 25.0, above the industry P\/E of 17.5. Looking ahead, the company has stressed an AI-led approach and strengthened its sales relationships with large clients. A broad client base in financial services provides recurring revenue, and its investments in cloud and data skills support growth.\"}},{\"@type\":\"Question\",\"name\":\"How has Ajanta Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P\/E of 36.3, above the industry P\/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.\"}},{\"@type\":\"Question\",\"name\":\"How has Global Health performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,206 crore in FY22 to Rs 4,509 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 196 crore in FY22 to Rs 554 crore in FY26, which works out to a compound annual growth rate of 29.6%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 1,326 crore. The company has a return on equity of 14.1%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 33,277 crore. The stock trades at a P\/E of 60.3, above the industry P\/E of 59.6. Looking ahead, management is widening its reach in Tier 2 cities while adding capacity at the Gurugram campus. A broader doctor base and a rising share of complex procedures such as cardiac and transplant care support the earnings mix as new facilities mature.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying IT services, pharma and hospital stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying IT services, pharma and hospital stocks. Client spending. Technology budgets can vary with global conditions. Pricing pressure. Generic prices can change by market. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of IT services, pharma and hospital stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IT Services, Pharma and Hospital Stocks with a strong future roadmap: Mphasis, Ajanta Pharma and Global Health. Compare price, valuation, return on equity and revenue growth as of 11 November 2026.<\/p>\n","protected":false},"author":34,"featured_media":344524,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[13959,3803,22534,22532,22533,7544,7567,7925,22531],"class_list":["post-344525","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-ajanta-pharma","tag-best-stocks","tag-branded-drug-maker-and-hospital-chain-stocks","tag-branded-medicine-and-care-network-shares","tag-digital-services-firm","tag-global-health","tag-it-services","tag-mphasis","tag-pharma-and-hospital-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["344524"],"rank_math_title":["IT Services, Specialty Pharma and Hospital Stocks"],"rank_math_description":["Compare 3 IT services, pharma and hospital stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 11 Nov 2026."],"rank_math_focus_keyword":["IT services, pharma and hospital stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-global-it-services-company-specialty-pharmaceuticals-company-and-multi.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=344525"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344525\/revisions"}],"predecessor-version":[{"id":344526,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/344525\/revisions\/344526"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/344524"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=344525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=344525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=344525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}